ESR1 and neoplasm: While AIs effectively block the conversion of androgens to estrogens to decrease ER-stimulated tumor growth, over time, circulating and intra-tumoral androgens can increase as an unintended consequence14–17, resulting in AR activation and resistance to AI therapy.